Filing Flows › Health Care › Inhibrx Biosciences (INBX)
Inhibrx Biosciences (INBX) earnings and revenue breakdown
Latest: Q2 2025 · 10-Q filed Aug 13, 2025 · Inhibrx Biosciences (INBX) Q2 2025 earnings results →
Q2 2025 Revenue up 1200% year over year to $1.3M
Inhibrx Biosciences made $1.3M in Q2 2025 (13× Y/Y). Operating margin n/m, net loss $28.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2025.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.3M in Q2 2025, up 1200% year over year.
Operating costs exceeded revenue by $27.4M, an operating margin of -2106.8%. Total costs fell 82% while revenue rose 1200%. The quarter ended with a net loss of $28.7M.
Operating cash flow was −$30.0M. Non-cash charges added back $662K of depreciation and amortization and $2.8M of share-based compensation. Working capital and other items used $4.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2025 | 10-Q | Aug 13, 2025 | $1.3M | 13× | n/m | −$28.7M | −$30.0M |
| Q4 2024 | 10-K | Mar 17, 2025 | $100K | -94% | n/m | −$47.9M | −$43.7M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Inhibrx Biosciences
We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms. We leverage our innovative protein engineering technologies and deep understanding of target biology to create therapeutic candidates with attributes and mechanisms we believe to be superior to current approaches and applicable to a range of challenging, validated targets with high potential.
In its own words, from its 10-K, filed Mar 19, 2026.
Inhibrx Biosciences against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: 13× against the peers' median +29%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| INBX Inhibrx Biosciences | Q2 2025 | $1.3M | 13× | n/m |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Inhibrx Biosciences 10-Q on SEC EDGAR · CIK 2007919 · Biological Products, (No Diagnostic Substances)
13F: who owns INBX and who is buying
More on INBX
- How Inhibrx Biosciences makes money: revenue by segment
- Inhibrx Biosciences next earnings date and what analysts expect
- Inhibrx Biosciences stock forecast, price target and fair value
- Who owns Inhibrx Biosciences stock: holders, funds and Congress trades
- Inhibrx Biosciences recalls, complaints and regulation
History
Every quarter: Q2 2025 results · Q4 2024 results